Stay updated on Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial
Sign up to get notified when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.

Latest updates to the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe clinical-trial page now presents the study record for Y90 radioembolization combined with nivolumab, including its status, eligibility criteria, treatment plan, and outcome measures, instead of an error page.SummaryDifference48%

- Check19 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces an NIH website transition and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check32 days agoChange DetectedThe footer's site revision identifier changed from v3.7.1 to v3.7.2, while the page continues to display a 403 error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study record URL now displays a 403 Forbidden error page, replacing the usual study details content. This indicates restricted access to the record rather than changes to the study data.SummaryDifference18%

Stay in the know with updates to Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.